TWI864155B - Npy2受體促效劑 - Google Patents

Npy2受體促效劑 Download PDF

Info

Publication number
TWI864155B
TWI864155B TW109139134A TW109139134A TWI864155B TW I864155 B TWI864155 B TW I864155B TW 109139134 A TW109139134 A TW 109139134A TW 109139134 A TW109139134 A TW 109139134A TW I864155 B TWI864155 B TW I864155B
Authority
TW
Taiwan
Prior art keywords
ethoxy
acetamido
group
compound
glu
Prior art date
Application number
TW109139134A
Other languages
English (en)
Chinese (zh)
Other versions
TW202134263A (zh
Inventor
彼得 威爾海穆 海貝爾
艾伯特 布雷納爾
夏綠蒂 史戴爾 曼德森
索倫 榮柏格 佩得森
史緹芬 彼德斯
Original Assignee
德商百靈佳殷格翰國際股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 德商百靈佳殷格翰國際股份有限公司 filed Critical 德商百靈佳殷格翰國際股份有限公司
Publication of TW202134263A publication Critical patent/TW202134263A/zh
Application granted granted Critical
Publication of TWI864155B publication Critical patent/TWI864155B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2271—Neuropeptide Y

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
TW109139134A 2019-11-11 2020-11-10 Npy2受體促效劑 TWI864155B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19208394 2019-11-11
EP19208394.7 2019-11-11

Publications (2)

Publication Number Publication Date
TW202134263A TW202134263A (zh) 2021-09-16
TWI864155B true TWI864155B (zh) 2024-12-01

Family

ID=68531488

Family Applications (1)

Application Number Title Priority Date Filing Date
TW109139134A TWI864155B (zh) 2019-11-11 2020-11-10 Npy2受體促效劑

Country Status (20)

Country Link
US (3) US20210139548A1 (https=)
EP (1) EP4058047A1 (https=)
JP (2) JP7821393B2 (https=)
KR (1) KR20220100925A (https=)
CN (1) CN114641303A (https=)
AR (1) AR120440A1 (https=)
AU (1) AU2020384729A1 (https=)
CA (1) CA3156452A1 (https=)
CL (1) CL2022001227A1 (https=)
CO (1) CO2022006046A2 (https=)
CR (1) CR20220206A (https=)
DO (1) DOP2022000097A (https=)
EC (1) ECSP22037660A (https=)
IL (1) IL292601A (https=)
JO (1) JOP20220110A1 (https=)
MX (1) MX2022005661A (https=)
PE (1) PE20221168A1 (https=)
PH (1) PH12022551101A1 (https=)
TW (1) TWI864155B (https=)
WO (1) WO2021094259A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20220206A (es) 2019-11-11 2022-06-16 Boehringer Ingelheim Int Agonistas del receptor npy2
JP7661478B2 (ja) * 2020-08-07 2025-04-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 可溶性ｎｐｙ２受容体アゴニスト
JP2025526148A (ja) * 2022-08-18 2025-08-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 長時間作用型ｇｌｐ－１／グルカゴン受容体アゴニスト及びｎｐｙ２受容体アゴニストを含む組合せ治療
CN120865433A (zh) * 2022-12-21 2025-10-31 勃林格殷格翰国际有限公司 Glp1/gip/npy2受体的三重激动剂
EP4670741A1 (en) 2023-04-28 2025-12-31 Pinotbio, Inc. ANTIBODY-DRUG CONJUGATE IN WHICH ONE OR MORE DRUG-BINDER CONJUGATES ARE LINKED TO AN ANTIBODY AND ITS PREPARATION METHOD

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011058165A1 (en) * 2009-11-13 2011-05-19 Novo Nordisk A/S Long-acting y2 receptor agonists
WO2016198682A1 (en) * 2015-06-12 2016-12-15 Novo Nordisk A/S Selective pyy compounds and uses thereof

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005053726A1 (en) 2003-11-25 2005-06-16 Bayer Pharmaceuticals Corporation Selective neuropeptide y2 receptor agonists
NZ579621A (en) 2004-02-11 2011-03-31 Amylin Pharmaceuticals Inc Hybrid polypeptides with selectable properties
EA011860B1 (ru) 2004-03-17 2009-06-30 7ТиЭм ФАРМА А/С Селективные агонисты рецептора y2 для терапевтического воздействия
WO2006049681A2 (en) 2004-08-30 2006-05-11 Bayer Pharmaceuticals Corporation Selective neuropeptide y2 receptor agonists
US8394765B2 (en) 2004-11-01 2013-03-12 Amylin Pharmaceuticals Llc Methods of treating obesity with two different anti-obesity agents
EP2360180A3 (en) 2004-12-13 2012-02-08 Amylin Pharmaceuticals Inc. Pancreatic polypeptide family motifs, polypeptides and methods comprising the same
CA2630649A1 (en) 2005-12-07 2007-06-14 F. Hoffmann-La Roche Ag Neuropeptide-2 receptor-agonists
CA2677932A1 (en) 2007-02-15 2008-08-21 Indiana University Research And Technology Corporation Glucagon/glp-1 receptor co-agonists
EP2158214B1 (en) 2007-06-15 2011-08-17 Zealand Pharma A/S Glucagon analogues
UA97707C2 (ru) 2007-11-14 2012-03-12 Амилин Фармасьютикалз, Инк. Способы лечения ожирения и заболеваний, расстройств, связанных с ожирением
FR2934058B1 (fr) 2008-07-15 2010-09-24 Centre Nat Rech Scient Dispositif de projection interferometrique a trois ouvertures pour produire une tache constituee de structures fines
EP2370462B1 (en) 2008-12-15 2014-07-16 Zealand Pharma A/S Glucagon analogues
JP5635531B2 (ja) 2008-12-15 2014-12-03 ジーランド ファーマ アクティーゼルスカブ グルカゴン類似体
ES2477880T3 (es) 2008-12-15 2014-07-18 Zealand Pharma A/S Análogos del glucagón
CN102282167B (zh) 2008-12-15 2014-08-13 西兰制药公司 胰高血糖素类似物
AU2010272944B2 (en) 2009-07-13 2015-11-19 Zealand Pharma A/S Acylated glucagon analogues
WO2011033068A1 (en) 2009-09-18 2011-03-24 Novo Nordisk A/S Long-acting y2 receptor agonists
CN102946875A (zh) 2010-05-05 2013-02-27 贝林格尔.英格海姆国际有限公司 组合疗法
UY33462A (es) 2010-06-23 2012-01-31 Zealand Pharma As Analogos de glucagon
US9169310B2 (en) 2010-06-24 2015-10-27 Zealand Pharma A/S Glucagon analogues
JP6121992B2 (ja) 2011-06-10 2017-04-26 ノヴォ ノルディスク アー／エス ポリペプチド
IN2014CN04401A (https=) 2011-12-23 2015-09-04 Zealand Pharma As
IN2014MN02304A (https=) 2012-05-03 2015-08-07 Zealand Pharma As
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
AU2014261111B2 (en) 2013-05-02 2017-03-16 Glaxosmithkline Intellectual Property Development Limited Therapeutic peptides
AR097701A1 (es) 2013-09-19 2016-04-13 Zealand Pharma As Análogos de amilina
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
PL3057984T3 (pl) 2013-10-17 2018-12-31 Zealand Pharma A/S Acylowane analogi glukagonu
CN105829339B (zh) 2013-11-06 2021-03-12 西兰制药公司 胰高血糖素-glp-1-gip三重激动剂化合物
CN105722854B (zh) 2013-11-14 2020-08-04 关键生物科学有限公司 用于治疗疾病和病症的降钙素模拟物
EP3068795B1 (en) * 2013-11-15 2019-03-06 Novo Nordisk A/S Hpyy(1-36) having a beta-homoarginine substitution at position 35
CN105722526B (zh) * 2013-11-15 2020-12-08 诺和诺德股份有限公司 选择性pyy化合物及其用途
BR112017019378A2 (pt) 2015-03-18 2019-02-19 Zealand Pharma A/S análogos de amilina
DK3283507T3 (da) 2015-04-16 2020-01-02 Zealand Pharma As Acyleret glucagonanalog
WO2016198624A1 (en) 2015-06-12 2016-12-15 Sanofi Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists
SG11201805586SA (en) 2015-12-31 2018-07-30 Hanmi Pharmaceutical Co Ltd Triple glucagon/glp-1/gip receptor agonist
EP3452088A4 (en) 2016-05-03 2020-04-15 The Scripps Research Institute TRKB AGONIST ANTIBODIES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES
US10071140B2 (en) 2016-09-09 2018-09-11 Zealand Pharma A/S Amylin analogues
JOP20190095A1 (ar) 2016-10-27 2019-04-28 Janssen Pharmaceutica Nv مركبات ببتيد تيروسين-تيروسين الحلقية كمعدلات لمستقبلات الببتيد العصبي y
TW201833131A (zh) 2016-12-02 2018-09-16 法商賽諾菲公司 作為胜肽類ｇｌｐ１／升糖素／ｇｉｐ受體促效劑之新化合物
AR110300A1 (es) 2016-12-02 2019-03-13 Sanofi Sa Compuestos como agonistas peptídicos trigonales de los receptores de glp1 / glucagón / gip
CN108289005B (zh) 2017-01-09 2021-06-29 中兴通讯股份有限公司 信令发送、接收方法及装置
GB201704429D0 (en) 2017-03-21 2017-05-03 Keybioscience Ag Calcitonin mimetics for treating diseases and disorders
US10793634B2 (en) 2017-06-09 2020-10-06 Boehringer Ingelheim International Gmbh Anti-TrkB antibodies
GB201720188D0 (en) 2017-12-04 2018-01-17 Imperial Innovations Ltd Analogues of PYY
US10581312B2 (en) 2017-12-29 2020-03-03 Texas Instruments Incorporated Multilevel converter using node voltage track and control
WO2019147650A1 (en) 2018-01-23 2019-08-01 Gila Therapeutics, Inc. Peptide yy pharmaceutical formulations, compositions, and methods
TWI847981B (zh) 2018-04-25 2024-07-11 比利時商健生藥品公司 類升糖素肽1 (glp-1)融合肽偶合環狀酪酪肽接合物及其用途
TW202535916A (zh) * 2018-11-01 2025-09-16 美商美國禮來大藥廠 蛋白質酪胺酸-酪胺酸類似物及其使用方法
CR20220206A (es) 2019-11-11 2022-06-16 Boehringer Ingelheim Int Agonistas del receptor npy2
JP7661478B2 (ja) 2020-08-07 2025-04-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 可溶性ｎｐｙ２受容体アゴニスト

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011058165A1 (en) * 2009-11-13 2011-05-19 Novo Nordisk A/S Long-acting y2 receptor agonists
WO2016198682A1 (en) * 2015-06-12 2016-12-15 Novo Nordisk A/S Selective pyy compounds and uses thereof

Also Published As

Publication number Publication date
US20210139548A1 (en) 2021-05-13
JP2023500895A (ja) 2023-01-11
AU2020384729A1 (en) 2022-04-14
AR120440A1 (es) 2022-02-16
JOP20220110A1 (ar) 2023-01-30
CO2022006046A2 (es) 2022-05-20
TW202134263A (zh) 2021-09-16
CR20220206A (es) 2022-06-16
JP7821393B2 (ja) 2026-02-27
ECSP22037660A (es) 2022-06-30
JP2026026081A (ja) 2026-02-16
PE20221168A1 (es) 2022-07-25
KR20220100925A (ko) 2022-07-18
PH12022551101A1 (en) 2023-11-13
US12559529B2 (en) 2026-02-24
EP4058047A1 (en) 2022-09-21
CL2022001227A1 (es) 2023-02-03
US20230340039A1 (en) 2023-10-26
US12054525B2 (en) 2024-08-06
US20250002544A1 (en) 2025-01-02
IL292601A (en) 2022-07-01
MX2022005661A (es) 2022-09-07
DOP2022000097A (es) 2022-06-15
WO2021094259A1 (en) 2021-05-20
CA3156452A1 (en) 2021-05-20
CN114641303A (zh) 2022-06-17

Similar Documents

Publication Publication Date Title
TWI864155B (zh) Npy2受體促效劑
US12083164B2 (en) Amylin analogues
JP7661478B2 (ja) 可溶性ｎｐｙ２受容体アゴニスト
JP6373270B2 (ja) 二重ｇｌｐ１／グルカゴンアゴニストとしてのエキセンディン−４誘導体
AU2011247452B2 (en) Peptide conjugates of GLP-1 receptor agonists and gastrin and their use
CN107108715A (zh) 胰高血糖素和glp‑1受体的共激动剂
CN105722526A (zh) 选择性pyy化合物及其用途
TW201706294A (zh) 胰澱素類似物
TW201542588A (zh) 糊精類似物
EA049057B1 (ru) Растворимые агонисты рецепторов npy2
EA047394B1 (ru) Агонисты рецептора npy2